Thirty-eight studies. Some in people, some in animals. All looking at the same question: what do GLP-1 medications actually do to the gut microbiome? 

The answer is more nuanced than most coverage of Ozempic and Mounjaro suggests. Some bacterial species increase in ways that look genuinely encouraging. Others decline. And the timing of those changes tells a story that most people on these medications have never heard.

The gut microbiome story most GLP-1 conversations are missing

If you are taking semaglutide, tirzepatide, or another GLP-1 medication, you have probably felt the obvious effects. Smaller portions feel like plenty. Cravings quiet down. The scale moves. But here is something most people on these medications have not been told: a year-long study found that the composition of your gut microbiome before you started treatment may actually predict how well you respond to it.

In plain terms, your gut bacteria going in might help explain why the same medication works remarkably well for one person and barely moves the needle for another.

This is not just a curious side note. It might be central to understanding how these medications actually work.

Why would a weight-loss drug affect gut bacteria at all?

GLP-1 medications were designed to work on your pancreas, brain, and stomach, slowing digestion, helping your body release insulin, and turning down hunger signals. Nobody designed them to touch your gut bacteria directly. But your gut bacteria and this hormone system have always been quietly connected, even before any medication enters the picture. (1)

Here is the simple version: certain gut bacteria break down fibre and produce helpful byproducts called short-chain fatty acids. These byproducts can signal your gut to release more of its own natural GLP-1. So diet, bacteria, and this hormone are already talking to each other in a loop, and the makeup of your gut bacteria can influence how much of this hormone your body produces on its own. (2) Add a GLP-1 medication into that loop, and you are not introducing something completely foreign. You are stepping into a conversation that was already happening.

What the research actually shows

The most thorough look at this so far pulled together 38 separate studies, some in people, some in animals, on GLP-1 drugs and gut bacteria. (3)

A few clear patterns emerged.

Liraglutide, an earlier GLP-1 medication, was the most studied and its story was the clearest. It consistently encouraged the growth of bacteria linked to better metabolic health. One standout was Akkermansia muciniphila, a bacterium that increased across five separate studies with not a single study reporting a drop. (3,4) This particular bacterium is repeatedly tied to a healthier gut lining and better blood sugar control, so its consistent increase is a genuinely encouraging sign.

Semaglutide, the ingredient in Ozempic and Wegovy, told a more complicated story. Some studies found the same helpful bacterium increased. Others found the overall variety of gut bacteria actually went down. (5) Variety matters because a gut with many different types of bacteria tends to be more resilient and better able to bounce back from stress, illness, or diet changes. A drop in variety is not necessarily alarming, but it is not automatically a win either. (6)

A separate study that followed people for a full year added another layer: semaglutide did not produce any statistically meaningful change in overall bacterial variety. However, the makeup of a person's gut bacteria before they started the drug predicted how well they would respond to it. (7) Your starting gut microbiome may help explain the variation in outcomes that researchers and clinicians keep observing.

So is it the drug, or is it the weight loss?

This is the question researchers keep coming back to, and the answer changes how we should think about all of this.

In that year-long study of people on semaglutide, the gut bacteria changes did not show up right away. They only became noticeable between months three and twelve of treatment. (7) That delay tells us something important. If the medication were directly rewiring gut bacteria the moment it entered the body, we would expect to see changes much sooner. Instead, the timing lines up with something else entirely: the slow, accumulated effect of eating differently, eating less, and carrying less body weight over time. (8)

In other words, your gut bacteria may be responding less to the medication itself and more to everything the medication sets into motion. Smaller meals. Different food choices. Gradual weight change. That is not a knock against these medications. It just means the real story is less "the drug directly reshapes your gut" and more "the changed habits reshape your gut, with the drug as the starting point."

What this means for you, day to day

None of this is a reason to worry about your prescription. It is a good reason to pay attention to what you are feeding the bacteria that are along for the ride.

Make fibre a priority, even when you are not that hungry. Fibre provides fermentable substrates for many gut microbes and can support the production of beneficial short-chain fatty acids. A diet rich in fibre-containing plant foods is associated with a more diverse and metabolically favourable gut microbiome.

Do not skip the variety. Aim for a broad range of vegetables, fruit, beans, whole grains, nuts, and seeds rather than relying on a single superfood. Dietary quality and a diverse range of plant foods are associated with differences in gut microbiome diversity and composition. (9)

Stay hydrated and keep moving. This is particularly practical if you are experiencing the gastrointestinal effects that can accompany GLP-1 treatment. GLP-1 medications can slow gastrointestinal motility, while physical activity is also associated with positive changes in the gut microbial environment.

Give it time. The microbiome does not necessarily change overnight. Current research suggests that changes observed during GLP-1 treatment may reflect a combination of the medication itself, weight loss, changes in diet and food intake, and other physiological changes. The relative contribution of each remains uncertain. (3)

The bigger picture: your mouth and gut are in this together

Your gut bacteria do not exist in a sealed-off system. They are in constant contact with the other microbial communities in your body, and the one in your mouth is more connected to your gut than most people realise.

The same appetite changes, altered eating patterns, and hydration shifts that reshape gut bacteria during GLP-1 treatment affect the oral microbiome too. Reduced food intake means fewer natural triggers for saliva production. Nausea and reflux, common during dose increases, create an acidic oral environment that favours the wrong bacterial species. The gut-oral axis means that what is happening in one community is rarely isolated from the other.

Supporting both sides of that system with a consistent, microbiome-aware daily routine is one of the most practical things you can do throughout treatment. Not as a corrective measure, but as an act of maintenance for two ecosystems that are working harder than usual to find their new balance.

Frequently asked questions

Does Ozempic hurt your gut bacteria?
Not in a straightforward way. Research shows semaglutide has mixed effects: some helpful bacteria increase, but the overall variety of bacteria sometimes decreases. Most researchers think this is a side effect of eating less and losing weight, not the drug directly harming your gut.

How long does it take for GLP-1s to change your gut bacteria?
Based on the longest study available on people, real changes showed up between three and twelve months of treatment, not in the first few weeks.

Can I take a probiotic while on a GLP-1 medication?
There is no strong evidence yet either way for probiotic supplements specifically alongside GLP-1s. Eating plenty of fibre-rich, varied whole foods is the best-supported way to support your gut bacteria during treatment.

Which GLP-1 medication has the best research on gut health?
Liraglutide has the most consistent published research showing helpful bacterial changes. Semaglutide has been studied more overall, but the results are more mixed and less consistent.